Skip to main content

A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

ABSTRACT Aims 

Because smoking cessation rates might be improved by combining drugs and by reducing post-cessation weight gain, we tested the smoking cessation efficacy, safety and effect on body weight of adding the nicotine patch to rimonabant, a cannabanoid type-1 receptor antagonist that reduces body weight. Design 

Randomized double-blind placebo-controlled trial. Setting 

Fifteen US research centers. Participants 

A total of 755 smokers (≥15 cigarettes/day). Intervention 

Rimonabant (20 mg daily) was given open-label for 9 weeks. The 735 participants completing week 1 were randomized at day 8 (target quit day) to add a nicotine patch (n = 369) or placebo patch (n = 366) for 10 weeks (21 mg daily for 8 weeks plus a 2-week taper). Participants received weekly smoking counseling and were followed for 24 weeks. Measurements 

Biochemically validated 4-week continuous abstinence at end-of-treatment (weeks 6–9; primary end-point); 7-day point prevalence abstinence at weeks 9 and 24; sustained abstinence (weeks 6–24); change in body weight; and adverse events. Findings 

Rimonabant plus nicotine patch was superior to rimonabant plus placebo in validated continuous abstinence at weeks 6–9 (39.0% versus 21.3%; odds ratio 2.36, 95% confidence interval: 1.71–2.37; P < 0.01) and in all other efficacy measures. Mean end-of-treatment weight gain among quitters did not differ between groups (0.04 kg for combination versus 0.49 kg for rimonabant only, P = 0.15) and was similar in weight-concerned smokers. Serious adverse event rates did not differ between groups. Depression- and anxiety-related adverse events occurred in 32 (4.2%) and 44 (5.8%) subjects, respectively; eight (1.1%) and nine (1.2%) subjects stopped the drug due to depression and anxiety, respectively. Conclusions 

Adding a nicotine patch to rimonabant was well tolerated and increased smoking cessation rates over rimonabant alone. There was little post-cessation weight gain in either group, even among weight-concerned smokers, during drug treatment.

Keywords: Nicotine patch; randomized controlled trial; rimonabant; smoking cessation

Document Type: Research Article

DOI: http://dx.doi.org/10.1111/j.1360-0443.2008.02454.x

Affiliations: 1: Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, 2: Oregon Health and Science University, Portland, OR, USA, 3: Mayo Clinic, Rochester, MN, USA 4: and University of Wisconsin Medical School, Madison, WI, USA

Publication date: February 1, 2009

bsc/add/2009/00000104/00000002/art00019
dcterms_title,dcterms_description,pub_keyword
6
5
20
40
5

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more